

SUPPLEMENTAL FIGURE

Kv3.3 channels harboring a mutation of spinocerebellar ataxia type 13 alter excitability and induce cell death in cultured cerebellar Purkinje cells

Tomohiko Irie, Yasunori Matsuzaki, Yuko Sekino, and Hirokazu Hirai


Supplemental Fig. S1



Supplemental Figure S1. Amino acid sequence alignment of hKv3.3 (accession number AF022150) with the mKv3.3 used in this experiment

The two sequences were aligned using Clone Manager 6 software (Scientific & Educational Software, Cary, NC). Hyphens represent gaps introduced to optimize the alignment. The six transmembrane domains are surrounded by squares. Residues conserved between hKv3.3 and mKv3.3 are colored blue.

Supplemental Fig. S2



Supplemental Figure S2. R424H mutant subunits work as a dominant-negative on WT mKv3.3 channels expressed in *Xenopus oocytes*


A, Representative traces evoked by stepping from -80 mV holding potential to voltages ranging from -70 to $+70$ mV in 10-mV increments. cRNA of WT mKv3.3 (Aa, WT), a mixture of WT and R424H mutant subunits at 1:1 ratio (Ab, WT+R424H), R424H mutant subunits (Ac, R424H), or nuclease-free water (Ad, Water) was injected into *Xenopus oocytes*.

B, Summary of the mean relative current amplitude. The amplitude was calculated from peak amplitude normalized by mean peak amplitude of WT-expressing oocytes at $+70$ mV voltage pulse.

C, Normalized conductance (G) of WT-expressing and WT+R424H-expressing oocytes are plotted as a function of voltage. G was obtained by dividing peak current by electrochemical driving force: $[G = I_K/(V - E_K)]$. The activation (G/G_{max}) curves were fit with the Boltzmann function, $G/G_{max} = 1/[1 + \exp(V_{1/2} - V)/k]$.

D, Comparison of activation τ between WT-expressing and WT+R424H mutant-expressing oocytes. Da, Representative traces evoked by stepping from -80 mV holding potential to $+40$ mV. The current traces are scaled to the same peak amplitude to compare the activation kinetics. Db, Comparison of τ_{acti} of WT mKv3.3 with that of WT+R424H mutant channels in *Xenopus oocytes*. τ_{acti} was obtained by fitting current traces with a single exponential function on the rising phases of the traces.

Supplemental Fig. S3




Supplemental Figure S3. Immunohistochemical characterization of mouse cerebellar cultures

A, Cerebellar cultures double-immunostained with anti-Calbindin and anti-NeuN antibodies at DIV 14. PCs (Calbindin-positive cells in *Aa*, double arrowheads) were NeuN-negative (*Ab* and *Ac*). *B*, Cultures double-immunostained with anti-GABA and anti-NeuN antibodies at DIV 16. GABAergic interneurons (GABA-positive small cells in *Ba* and *Bc*, arrowheads) were also NeuN-negative. Double arrowheads in *Ba* and *Bc* indicate a putative PC. *C*, Cultures triple-immunostained with anti-GFP, anti-Calbindin, and anti-Kv3.3 antibodies at DIV 14. PCs but not other cerebellar

neurons expressed mKv3.3 channels. In *C*, GFP-expressing cerebellar cultures were used to visualize the neurons. *D*, Cerebellar cultures double-immunostained with anti-Kv3.4 and anti-Calbindin antibodies, showing the expression of Kv3.4 in PCs. *E*, Immunofluorescence images of cerebellar cultures infected with lentiviral vectors expressing GFP (*Ea-Ea''*) or WT subunits (*Eb* and *Eb'*). The cultures were double-immunostained with anti-GFP and anti-Kv3.3 antibodies. The fluorescence images were taken in the same conditions for the quantitative analysis. PCs are indicated by arrowheads. Panel *Ea''* is a contrast-enhanced image of *Ea'* that shows faint but some expression of endogenous mKv3.3 in PCs expressing GFP alone. *Ec*, Quantitative analysis of immunofluorescence intensity for Calbindin and Kv3.3. AU, arbitrary unit. In *A-E*, The following primary and secondary antibodies were used. Primary antibodies: mouse monoclonal anti-Calbindin antibody (*A*, *C*, and *D*, 1:2,000-diluted, No.300, Swant; Bellinzona, Switzerland), mouse monoclonal anti-NeuN antibody (*A* and *B*, 1:2,000-diluted), and rabbit polyclonal anti-GABA antibody (*B*, 1:1,000-diluted, A2052; Sigma-Aldrich), guinea pig polyclonal anti-GFP antibody (*C* and *E*, 1:1,000-diluted), and rabbit polyclonal anti-Kv3.3 antibody [*C* and *E*, 1:2,000-diluted, APC-102; Alomone labs, Jerusalem, Israel; This antibody is raised from the peptide KSPITPGSRGRYSRDRAC corresponding with residues 701-718 of rat Kv3.3a channels, which have a sequence that is identical to 692-709 of the mKv3.3 channels (Chang *et al.*, 2007)]. Secondary antibodies: AF 568-conjugated goat anti-rabbit IgG antibody (3A), AF 680-conjugated goat anti-mouse IgG antibody (*A* and *D*), AF 488-conjugated goat anti-rabbit IgG antibody (*B*, A-11008; Invitrogen), AF 568-conjugated goat anti-mouse IgG antibody (*B*, *C*, and *E*, A-11031; Invitrogen), AF 488-conjugated goat anti-guinea pig IgG antibody (*C* and *E*), AF 680-conjugated goat anti-rabbit IgG antibody (*C* and *E*, A-21109; Invitrogen). All secondary antibodies were used at the concentration of 5 μ g/ml. The incubation conditions were same as Fig. 2. For immunolabeling of Kv3.4 protein in cerebellar cultures (*D*), goat serum was excluded from the incubation buffer. Cerebellar cultures were immunolabeled with goat polyclonal anti-hKv3.4 antibody (1:500-diluted, sc-104343; Santa Cruz Biotechnology, Santa Cruz, CA) and mouse monoclonal anti-Calbindin antibody, and then with AF 568-conjugated donkey anti-goat IgG antibody (A-11057; Invitrogen). After blocking with the incubation buffer containing 10% normal goat serum, the cultures were further incubated with AF 680-conjugated goat anti-mouse IgG antibody.


Supplemental Fig. S4



Supplemental Figure S4. Recordings of spontaneous action potentials from PCs

A, Immunohistochemical identification of PCs. PCs were stained intracellularly with biocytin infused via patch pipettes, fixed in 4% (w/v) formaldehyde, and incubated with mouse monoclonal anti-Calbindin antibody and guinea pig polyclonal anti-GFP antibody. The samples were further incubated with AF 568 streptavidin (S-11226, Invitrogen), AF 488-conjugated goat anti-guinea pig IgG antibody, and AF 680-conjugated goat anti-mouse IgG antibody. The incubation conditions were the same as in Fig. 2. B and C, Representative spontaneous firing recorded from GFP-expressing PC (B) and R424H mutant-expressing PC (C) at DIV 8.

Supplemental Fig. S5



Supplemental Figure S5. Comparison of I_{Na} recorded under the whole-cell configuration

I_{Na} was recorded in HEPES-buffered ACSF in which 140 NaCl (in mM) was replaced with 117 NaCl, 22 TEA-Cl, 3 CsCl, and 2 4-aminopyridine, 0.2 CdCl₂, 0.1 picrotoxin, and 0.02 DNQX; RT (20–22°C). A CsCl-based internal solution was used (in mM): 140 CsCl, 10 NaCl, 0.2 EGTA, 10 biocytin, and 10 HEPES (pH 7.3 with CsOH, $E_{Na} = 63.4$ mV). The liquid junction potential (–5 mV) was corrected off-line. *A*, Representative traces of I_{Na} activated with 50-ms voltage steps from –85 mV to voltages ranging from –50 to –30 mV in 5-mV increments. The leak currents were subtracted on-line the p/4 protocol and the I_{Na} was confirmed by application of TTX (0.001 mM, data not shown). *B*, The current-voltage relation of peak I_{Na} . In this figure, an asterisk (*) indicates statistical significance between GFP alone and R424H mutant, and a number sign (#) between WT mKv3.3 and R424H. * $p < 0.05$, # $p < 0.05$, and ### $p < 0.01$. *Ca*, The conductance-voltage relations, which were obtained in the same way as those in Supplemental Fig. S2C. E_{Na} was used for the equilibrium potential. *Cb* and *Cc*, k (*Cb*) and $V_{1/2}$ (*Cc*) of activation for R424H mutant-expressing PCs did not show significant difference compared to those for the control group. *D*, The steady-state inactivation was determined by holding cells at –85 mV before applying a 200-ms pre-pulse to potentials between –125 and –20 mV in 5-mV increments, followed by a 100-ms test pulse to –20 mV. *Da*, Steady-state inactivation curves were obtained in the same way as those in Fig. 1Bc. *Db* and *Dc*, k (*Db*) and $V_{1/2}$ (*Dc*) for R424H mutant-expressing PCs did not show significant difference compared to those for the control group.